CUSIP: 59102M104
Q1 2024 13F Holders as of 31 Mar 2024
-
Type / Class
-
Equity / COM
-
Total 13F shares
-
13,335,479
-
Share change
-
+13,335,479
-
Total reported value
-
$140,258,517
-
Price per share
-
$10.55
-
Number of holders
-
49
-
Value change
-
+$140,258,517
-
Number of buys
-
49
Quarterly Holders Quick Answers
What is CUSIP 59102M104?
CUSIP 59102M104 identifies MGX - Metagenomi Therapeutics, Inc. - COM in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 59102M104:
Institutional Holders of Metagenomi Therapeutics, Inc. - COM (MGX) as of Q1 2024
As of 31 Mar 2024,
Metagenomi Therapeutics, Inc. - COM (MGX) was held by
49 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
13,335,479 shares.
The largest 10 holders included
RA CAPITAL MANAGEMENT, L.P., Novo Holdings A/S, FARALLON CAPITAL MANAGEMENT LLC, PFM Health Sciences, LP, HHLR ADVISORS, LTD., MILLENNIUM MANAGEMENT LLC, CITADEL ADVISORS LLC, EVENTIDE ASSET MANAGEMENT, LLC, Sozo Ventures GP II, L.P., and Deep Track Capital, LP.
This page lists
49
institutional shareholders reporting positions in this security
for the Q1 2024 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.